C117307
溴代环丙烷
99%
别名:
环丙基溴
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C3H5Br
化学文摘社编号:
分子量:
120.98
UNSPSC Code:
12352100
NACRES:
NA.22
PubChem Substance ID:
EC Number:
224-375-7
Beilstein/REAXYS Number:
1900287
MDL number:
产品名称
溴代环丙烷, 99%
InChI key
LKXYJYDRLBPHRS-UHFFFAOYSA-N
InChI
1S/C3H5Br/c4-3-1-2-3/h3H,1-2H2
SMILES string
BrC1CC1
assay
99%
form
liquid
refractive index
n20/D 1.458 (lit.)
bp
69 °C (lit.)
density
1.51 g/mL at 25 °C (lit.)
storage temp.
2-8°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
General description
溴环丙烷是有机合成的关键中间体，也是药物开发中构建多种化学结构的基础材料。
signalword
Danger
hcodes
Hazard Classifications
Flam. Liq. 2
存储类别
3 - Flammable liquids
wgk
WGK 3
flash_point_f
21.2 °F - closed cup
flash_point_c
-6 °C - closed cup
ppe
Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter
法规信息
危险化学品
此项目有
Mechanism-Driven Elaboration of an Enantioselective Bromocyclopropanation Reaction of Allylic Alcohols
S Taillemaud, et al.
Angewandte Chemie (International Edition in English), 127, 14314-14318 (2015)
Carmen Abate et al.
Journal of medicinal chemistry, 57(8), 3314-3323 (2014-04-05)
Despite the promising potentials of σ2 receptors in cancer therapy and diagnosis, there are still ambiguities related to the nature and physiological role of the σ2 protein. With the aim of providing potent and reliable tools to be used in
Carmen Abate et al.
ChemMedChem, 6(1), 73-80 (2010-11-12)
Many new chemotherapeutic agents are under preclinical investigation and, despite efforts to more selectively target cancer cells, limitations such as toxicity and inherent resistance are often encountered. Therefore, alternative strategies are needed to treat cancer and overcome such limitations. We
Maria Laura Pati et al.
Pharmacological research, 117, 67-74 (2016-12-23)
A controversial relationship between sigma-2 and progesterone receptor membrane component 1 (PGRMC1) proteins, both representing promising targets for the therapy and diagnosis of tumors, exists since 2011, when the sigma-2 receptor was reported to be identical to PGRMC1. Because a
Francesco Berardi et al.
Journal of medicinal chemistry, 52(23), 7817-7828 (2009-10-22)
sigma(2)-Agonist 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (7, PB 28), which proved to revert doxorubicin resistance in breast cancer cells, was taken as a template to prepare new analogs. One of the two basic N-atoms was alternatively replaced by a methine or converted into an
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持